New York, USA – November 23, 2020 – Since its emergence in December 2019, COVID-19 has quickly evolved into a global pandemic. Though public health measures have been taken, no effective drugs or vaccines have been proved to be both effective and safe yet. To help global scientists accelerate their research of fighting with SARS-CoV-2, scientists at Creative Biolabs are ready to provide a wide range of drug discovery services.
The antiviral drug discovery has already covered antiviral peptide (SARS-CoV-2 peptide microarray analysis, etc), protease inhibitors, broad-spectrum antiviral drug, RNA synthesis inhibitors, Abelson Kinase inhibitors, nucleoside analogue (such as Remdesivir, Ribavirin, BCX4430, Acyclovir Fleximer), etc. Now, Creative Biolabs has optimized its one-stop vaccine discovery services, covering virus-like particles based vaccine, mRNA vaccine and recombinant subunit vaccine for SARS-CoV-2.
• Virus-like Particles (VLPs) Based Vaccine for SARS-CoV-2
VLPs-based vaccines have been developed as a new generation of non-egg-based, cell culture-derived vaccine candidates against virus infection. Creative Biolabs offers VLP-based vaccine development services, mastering a variety of VLP expression systems, such as mammalian cells, yeast, recombinant vaccinia virus and baculovirus expression systems. Genetic engineering is also used to improve the immunogenicity of VLP and enhance the protective effect against SARS-CoV-2 challenge.
• mRNA Vaccine Design for SARS-CoV-2
As a member of ß-coronavirus genus, SARS-CoV-2’s transcription involves a discontinuous RNA synthesis during the extension of negative copies of subgenomic mRNAs. Based on the understanding of coronaviruses, Creative Biolabs is skillful at quickly synthesizing mRNAs of multiple different antigen sequences against key targets of SARS-CoV-2, and obtaining effective antigens through screening to develop mRNA vaccines.
• Recombinant Subunit Vaccine for SARS-CoV-2
Subunit vaccines, which are one of the two most commonly adopted vaccine forms in the market, are safer than whole-virion vaccines due to the decreased risk of exposure during manufacturing.
This trimeric S protein on SARS-CoV-2 is a very attractive candidate for developing subunit vaccines. With a cutting-edge vaccine development platform, Creative Biolabs is capable of producing novel, covalently-trimerized fusion proteins. The comprehensive SARS-CoV-2 S protein subunit vaccine development services include gene synthesis, vector construction, protein expression and purification, immunoassay.
“Our unique combination of expertise in immunology and antiviral vaccine research makes us an ideal partner for your SARS-CoV-2 vaccine discovery,” introduced by a senior scientist at Creative Biolabs. “We can help clients with each stage of their projects, including primary research, antigen development, testing for attenuation, antibody and antigen detection and stability testing.”
More information can be found on https://sars-cov-2.creative-biolabs.com.
About Creative Biolabs
Empowered by leading technology and over 15 years of experience in biomedical science, Creative Biolabs has successfully accomplished numerous challenging projects for customers in requirements with accumulated experience in drug discovery and vaccine development. Especially in the field of antiviral drugs and vaccines, Creative Biolabs provides drug discovery, vaccine design, preclinical evaluation of drugs and vaccines, and in vitro diagnostic services at the world-leading level.